Abstract
Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma. These advances are largely due to thalidomide-, lenalidomide-, and bortezomib-based combinations that have improved response rates, not only in patients with untreated disease, but also in those with relapsed and/or refractory myeloma, in some cases producing response rates up to 85%. Eventually, however, nearly all patients relapse, emphasizing a continuing role for the introduction of investigational agents that overcome drug resistance. This article will review the current role for thalidomide, lenalidomide, and bortezomib-based combinations, as well as some preliminary findings for promising investigational agents currently in clinical trials for patients with relapsed and/or refractory disease.
Original language | English (US) |
---|---|
Pages (from-to) | S25-S42 |
Journal | Medical Oncology |
Volume | 27 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - Jun 2010 |
Keywords
- Multiple myeloma
- Refractory
- Relapsed
- Treatment advances
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research